JP2011521627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521627A5 JP2011521627A5 JP2011508686A JP2011508686A JP2011521627A5 JP 2011521627 A5 JP2011521627 A5 JP 2011521627A5 JP 2011508686 A JP2011508686 A JP 2011508686A JP 2011508686 A JP2011508686 A JP 2011508686A JP 2011521627 A5 JP2011521627 A5 JP 2011521627A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- igf
- targeted therapeutic
- therapeutic fusion
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 54
- 102000037865 fusion proteins Human genes 0.000 claims description 54
- 230000001225 therapeutic effect Effects 0.000 claims description 52
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 33
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000002132 lysosomal effect Effects 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 11
- 102000057877 human IGF2 Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 102000004961 Furin Human genes 0.000 claims description 9
- 108090001126 Furin Proteins 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 6
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 claims description 6
- 108010001127 Insulin Receptor Proteins 0.000 claims description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 102000003746 Insulin Receptor Human genes 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims description 4
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 102000045921 human GAA Human genes 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 claims description 2
- 102220576120 Oligodendrocyte transcription factor 1_Y27W_mutation Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102200149451 rs1800361 Human genes 0.000 claims description 2
- 102220060032 rs772591447 Human genes 0.000 claims description 2
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims 2
- 102100026189 Beta-galactosidase Human genes 0.000 claims 2
- 102000004882 Lipase Human genes 0.000 claims 2
- 108090001060 Lipase Proteins 0.000 claims 2
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims 2
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 claims 1
- 102100022146 Arylsulfatase A Human genes 0.000 claims 1
- 102100031491 Arylsulfatase B Human genes 0.000 claims 1
- 101710124976 Beta-hexosaminidase A Proteins 0.000 claims 1
- 101710124978 Beta-hexosaminidase B Proteins 0.000 claims 1
- 102100032487 Beta-mannosidase Human genes 0.000 claims 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims 1
- 102100028496 Galactocerebrosidase Human genes 0.000 claims 1
- 108010042681 Galactosylceramidase Proteins 0.000 claims 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 1
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 108010017544 Glucosylceramidase Proteins 0.000 claims 1
- 102000053187 Glucuronidase Human genes 0.000 claims 1
- 108010060309 Glucuronidase Proteins 0.000 claims 1
- 108010000540 Hexosaminidases Proteins 0.000 claims 1
- 102000002268 Hexosaminidases Human genes 0.000 claims 1
- 102000004627 Iduronidase Human genes 0.000 claims 1
- 108010003381 Iduronidase Proteins 0.000 claims 1
- 102100036721 Insulin receptor Human genes 0.000 claims 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims 1
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 claims 1
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 claims 1
- 101000652829 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Exo-alpha-sialidase Proteins 0.000 claims 1
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims 1
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- 102000005262 Sulfatase Human genes 0.000 claims 1
- 108010044965 UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase Proteins 0.000 claims 1
- 102000005421 acetyltransferase Human genes 0.000 claims 1
- 108020002494 acetyltransferase Proteins 0.000 claims 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims 1
- 108010012864 alpha-Mannosidase Proteins 0.000 claims 1
- 102000019199 alpha-Mannosidase Human genes 0.000 claims 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 claims 1
- 108010055059 beta-Mannosidase Proteins 0.000 claims 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108060007951 sulfatase Proteins 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5133608P | 2008-05-07 | 2008-05-07 | |
| US61/051,336 | 2008-05-07 | ||
| US14410609P | 2009-01-12 | 2009-01-12 | |
| US61/144,106 | 2009-01-12 | ||
| PCT/US2009/043207 WO2009137721A2 (en) | 2008-05-07 | 2009-05-07 | Lysosomal targeting peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521627A JP2011521627A (ja) | 2011-07-28 |
| JP2011521627A5 true JP2011521627A5 (cg-RX-API-DMAC7.html) | 2013-05-23 |
| JP5627571B2 JP5627571B2 (ja) | 2014-11-19 |
Family
ID=41265422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508686A Active JP5627571B2 (ja) | 2008-05-07 | 2009-05-07 | リソソーム標的化ペプチドおよびその使用 |
Country Status (17)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5967861B2 (ja) | 2007-04-03 | 2016-08-10 | オキシレイン ユーケー リミテッド | 分子のグリコシル化 |
| CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| JP5616336B2 (ja) | 2008-06-26 | 2014-10-29 | オルファザイム エーピーエスOrphazyme Aps | 酵素活性の調節因子としてのHsp70の使用 |
| US8785168B2 (en) * | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| KR102000383B1 (ko) | 2009-09-29 | 2019-07-15 | 유니버시테이트 젠트 | 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해 |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物 |
| US20130053550A1 (en) | 2009-11-19 | 2013-02-28 | Oxyrane Uk Limited | Yeast strains producing mammalian-like complex n-glycans |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランn−スルファターゼのcns送達のための方法および組成物 |
| CA2803166C (en) | 2010-06-25 | 2023-03-07 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| CN103269709A (zh) | 2010-06-25 | 2013-08-28 | 夏尔人类遗传性治疗公司 | Sanfilippo综合症类型B的治疗 |
| JP6045493B2 (ja) | 2010-06-25 | 2016-12-14 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼaのcns送達の方法および組成物 |
| BR112012033214B1 (pt) | 2010-06-25 | 2020-11-03 | Shire Human Genetic Therapies, Inc. | uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente |
| KR20130043165A (ko) | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| JP6131190B2 (ja) | 2010-09-29 | 2017-05-17 | オキシレイン ユーケー リミテッド | リン酸化n−グリカンの脱マンノシル化 |
| BR112013007616B1 (pt) | 2010-09-29 | 2023-01-24 | Oxyrane Uk Limited | Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero |
| US9662375B2 (en) | 2010-11-30 | 2017-05-30 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
| CN102121021B (zh) * | 2010-12-21 | 2012-05-02 | 南京师范大学 | 绵羊IFN-γ诱导的溶酶体巯基还原酶cDNA及其克隆方法和重组应用 |
| US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| BR112013022557A2 (pt) * | 2011-03-04 | 2017-08-01 | Shire Human Genetic Therapies | ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos |
| LT2714752T (lt) | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| CA2867237C (en) | 2012-03-15 | 2024-01-02 | Wouter Vervecken | Methods and materials for treatment of pompe's disease |
| WO2014082080A2 (en) * | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| ES2679374T3 (es) | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| WO2016025519A1 (en) * | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| US10709700B2 (en) | 2014-09-15 | 2020-07-14 | Orphazyme A/S | Arimoclomol formulation |
| JP6851964B2 (ja) | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| WO2016065319A1 (en) * | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| MA41022A (fr) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
| HK1253529A1 (zh) | 2015-11-06 | 2019-06-21 | Biomarin Pharmaceutical Inc. | 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定 |
| IL299470B2 (en) | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| EP3419651B1 (en) | 2016-02-24 | 2023-10-25 | BioMarin Pharmaceutical Inc. | Improved naglu fusion protein formulation |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
| ES2831764T3 (es) | 2016-04-29 | 2021-06-09 | Orphazyme As | Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa |
| CN119113091A (zh) | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| US10325665B2 (en) * | 2017-12-08 | 2019-06-18 | Intel Corporation | Block by deck operations for NAND memory |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| TW202344691A (zh) | 2018-04-30 | 2023-11-16 | 美商阿米庫斯醫療股份有限公司 | 基因治療構築體及使用方法 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| JP7577650B2 (ja) | 2018-10-10 | 2024-11-05 | アミカス セラピューティックス インコーポレイテッド | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
| WO2020102645A1 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus for treating pompe disease |
| JP7458404B2 (ja) | 2018-12-20 | 2024-03-29 | アーマジェン・インコーポレイテッド | イズロン酸-2-スルファターゼ免疫グロブリン融合タンパク質の精製 |
| US20220193261A1 (en) * | 2019-04-30 | 2022-06-23 | The Trustees Of The University Of Pennsylvania | Compositions useful for treatment of pompe disease |
| CN112546228A (zh) * | 2019-09-10 | 2021-03-26 | 中国科学院上海营养与健康研究所 | 非igf1r结合型的物质在预防和/或治疗炎症性疾病中的应用 |
| WO2021102107A1 (en) * | 2019-11-19 | 2021-05-27 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders |
| EP4081241A4 (en) | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| CN113105526B (zh) * | 2020-01-09 | 2022-04-26 | 北京鲲达宇科技有限公司 | 多肽及其应用、包括该多肽的探针、试剂盒 |
| WO2022104261A1 (en) * | 2020-11-16 | 2022-05-19 | Avrobio, Inc. | Compositions and methods for treating pompe disease |
| EP4247792A1 (en) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| CN114573714B (zh) * | 2021-03-15 | 2023-03-31 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
| EP4359425B1 (en) | 2021-06-21 | 2026-08-05 | Juvena Therapeutics, Inc. | Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury |
| EP4359430A4 (en) | 2021-06-23 | 2025-07-16 | Lycia Therapeutics Inc | BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES |
| CN117343197A (zh) * | 2021-10-15 | 2024-01-05 | 中山大学 | 重组融合抗体 |
| CN114404615B (zh) * | 2022-02-11 | 2024-05-24 | 国家纳米科学中心 | 一种多肽纳米胶束制剂、其制备方法及应用 |
| NL2031676B1 (en) | 2022-04-22 | 2023-11-07 | Univ Erasmus Med Ct Rotterdam | Gene therapy for Pompe Disease |
| WO2024096738A1 (en) | 2022-11-01 | 2024-05-10 | Erasmus University Medical Center Rotterdam | Gene therapy constructs for metabolic disorders |
| AU2023383441A1 (en) | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025171294A1 (en) * | 2024-02-07 | 2025-08-14 | University Of Massachusetts | Lysosome-targeting chimeras and methods of use |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309776A (en) * | 1980-05-13 | 1982-01-12 | Ramon Berguer | Intravascular implantation device and method of using the same |
| US4749570A (en) * | 1981-12-31 | 1988-06-07 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0189481B1 (en) * | 1984-07-13 | 1991-01-23 | Chiron Corporation | Insulin-like growth factor ii |
| ATE63757T1 (de) | 1985-03-28 | 1991-06-15 | Chiron Corp | Expression durch verwendung von fusionsgenen fuer proteinproduktion. |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5470828A (en) * | 1987-12-24 | 1995-11-28 | Gropep Pty. Ltd. | Peptide analogs of insulin-like growth factor II |
| US5817623A (en) * | 1995-03-06 | 1998-10-06 | Univ Colorado State Res Found | Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II |
| US5236838A (en) * | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US6451600B1 (en) * | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) * | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US6610299B1 (en) * | 1989-10-19 | 2003-08-26 | Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5248606A (en) | 1990-06-11 | 1993-09-28 | Dowelanco | Dna encoding inactive precursor and active forms of maize ribosome inactivating protein |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US5633235A (en) * | 1991-04-19 | 1997-05-27 | Regents Of The University Of Michigan | Triciribine and analogs as antiviral drugs |
| FR2676058B1 (fr) * | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
| US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| US5736363A (en) * | 1991-07-29 | 1998-04-07 | British Bio-Technology Limited | IGF-II analogues |
| AU2752892A (en) | 1991-09-26 | 1993-04-27 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| JPH07509444A (ja) | 1991-11-26 | 1995-10-19 | アルカーメス・インコーポレーテツド | トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法 |
| US5258453A (en) * | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| EP0646178A1 (en) * | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5981194A (en) * | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US5476779A (en) * | 1992-09-30 | 1995-12-19 | University Of Maryland At College Park | DNA encoding insulin-like growth factor II isolated from rainbow trout |
| EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5798366A (en) * | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US5704910A (en) * | 1995-06-05 | 1998-01-06 | Nephros Therapeutics, Inc. | Implantable device and use therefor |
| US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US20020013953A1 (en) * | 1995-08-02 | 2002-01-31 | Reuser Arnold J. | Compositions and methods for treating enzyme deficiency |
| US6118045A (en) * | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| CA2233343A1 (en) * | 1995-09-29 | 1997-04-03 | Biomarin Pharmaceutical, Inc. | Use of heparinases to decrease inflammatory responses |
| US6348194B1 (en) * | 1995-11-13 | 2002-02-19 | Ixsys Incorporated | Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| US6344436B1 (en) * | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
| US6273598B1 (en) * | 1996-01-22 | 2001-08-14 | Creative Biomolecules, Inc. | Computer system and methods for producing morphogen analogs of human OP-1 |
| US6020144A (en) * | 1996-09-12 | 2000-02-01 | Symbiontics, Inc. | Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6235874B1 (en) * | 1997-01-10 | 2001-05-22 | Academia Sinica | Production of biologically active recombinant insulin-like growth factor II polypeptides |
| US6329501B1 (en) * | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| ATE359561T1 (de) * | 1997-06-02 | 2007-05-15 | Univ Johns Hopkins | Rechnerverfahren freie energieberechnung für ligandenentwurf verwendend und die voraussage von bindenden zielen |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| EP1027069B1 (en) * | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| NZ510358A (en) * | 1998-08-11 | 2002-09-27 | Large Scale Biology Corp | Method for recovering proteins from the interstitial fluid of plant tissues |
| DK2020438T3 (en) * | 1998-12-07 | 2018-07-23 | Genzyme Corp | Treatment of Pompe disease |
| US6596500B1 (en) * | 1998-12-08 | 2003-07-22 | The General Hospital Corporation | Binding of retinoids to M6P/IGF-II receptor |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US6770468B1 (en) * | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6534300B1 (en) * | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6569661B1 (en) * | 1999-11-12 | 2003-05-27 | Biomarin Pharmaceutical Inc. | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
| DK174076B1 (da) | 2000-01-21 | 2002-05-21 | Flowcon Int As | Reguleringsindsats til anbringelse i ventiler og ventilenhed |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7056712B2 (en) * | 2000-07-18 | 2006-06-06 | Duke University | Treatment of glycogen storage disease type II |
| AUPR030900A0 (en) * | 2000-09-22 | 2000-10-12 | Queensland University Of Technology | Growth factor complex |
| WO2002044355A2 (en) | 2000-11-30 | 2002-06-06 | Symbiontics, Inc. | Protozoan expression systems for lysosomal storage disease genes |
| US20020142299A1 (en) * | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| US20030004236A1 (en) * | 2001-04-20 | 2003-01-02 | Meade Thomas J. | Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003102583A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| EP1436316B1 (en) * | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US6800472B2 (en) * | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
| US6905856B2 (en) * | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
| WO2003057179A2 (en) | 2002-01-11 | 2003-07-17 | Biomarin Pharmaceutical, Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| US7658916B2 (en) * | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| JP4828121B2 (ja) * | 2002-05-29 | 2011-11-30 | バイオマリン ファーマシューティカル インコーポレイテッド | 標的化治療的タンパク質 |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| PT1587923E (pt) * | 2003-01-22 | 2011-12-07 | Univ Duke | Construções melhoradas para a expressão de polipéptidos lisossomais |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| WO2005077333A2 (en) * | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
| US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
| AU2006203882B2 (en) * | 2005-01-07 | 2011-05-12 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| ES2366059T3 (es) * | 2006-03-17 | 2011-10-14 | Biomarin Pharmaceutical Inc. | Ensayos para la detección de anticuerpos anti-enzimas lisosómicas. |
| CL2007001614A1 (es) * | 2006-06-09 | 2008-08-08 | Novartis Ag | Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t |
| WO2008109677A2 (en) * | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| WO2009137721A2 (en) | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US8785168B2 (en) * | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| CN103269709A (zh) * | 2010-06-25 | 2013-08-28 | 夏尔人类遗传性治疗公司 | Sanfilippo综合症类型B的治疗 |
| ES2679374T3 (es) * | 2012-11-27 | 2018-08-24 | Biomarin Pharmaceutical Inc. | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
-
2009
- 2009-05-07 WO PCT/US2009/043207 patent/WO2009137721A2/en not_active Ceased
- 2009-05-07 ES ES17182845T patent/ES2830350T3/es active Active
- 2009-05-07 CA CA2723412A patent/CA2723412A1/en active Pending
- 2009-05-07 EP EP20184387.7A patent/EP3778652A1/en active Pending
- 2009-05-07 EP EP17152899.5A patent/EP3187508B1/en active Active
- 2009-05-07 AU AU2009244148A patent/AU2009244148B2/en active Active
- 2009-05-07 EP EP17182845.2A patent/EP3272773B8/en active Active
- 2009-05-07 FI FIEP17152899.5T patent/FI3187508T3/fi active
- 2009-05-07 BR BR122017015900-3A patent/BR122017015900A2/pt not_active Application Discontinuation
- 2009-05-07 JP JP2011508686A patent/JP5627571B2/ja active Active
- 2009-05-07 PT PT97437073T patent/PT2279210T/pt unknown
- 2009-05-07 BR BRPI0912225-7A patent/BRPI0912225A2/pt not_active Application Discontinuation
- 2009-05-07 US US12/991,104 patent/US20110223147A1/en not_active Abandoned
- 2009-05-07 PL PL09743707T patent/PL2279210T3/pl unknown
- 2009-05-07 CN CN200980123156.6A patent/CN102066422B/zh active Active
- 2009-05-07 HR HRP20170698TT patent/HRP20170698T1/hr unknown
- 2009-05-07 ES ES09743707.3T patent/ES2629853T3/es active Active
- 2009-05-07 HU HUE09743707A patent/HUE034850T2/en unknown
- 2009-05-07 DK DK17152899.5T patent/DK3187508T3/da active
- 2009-05-07 DK DK09743707.3T patent/DK2279210T3/en active
- 2009-05-07 EP EP09743707.3A patent/EP2279210B1/en active Active
-
2010
- 2010-11-03 IL IL209091A patent/IL209091A/en active IP Right Grant
-
2012
- 2012-02-17 US US13/399,844 patent/US8563691B2/en active Active
-
2014
- 2014-11-07 US US14/535,505 patent/US9469683B2/en active Active
-
2016
- 2016-09-23 US US15/274,115 patent/US20170007680A1/en not_active Abandoned
-
2017
- 2017-05-25 CY CY20171100545T patent/CY1119183T1/el unknown
- 2017-07-24 US US15/657,764 patent/US11351231B2/en active Active
-
2020
- 2020-05-08 US US16/869,862 patent/US20210069304A1/en not_active Abandoned
-
2022
- 2022-06-01 US US17/829,620 patent/US20220354934A1/en active Pending
- 2022-07-27 US US17/815,468 patent/US20230241187A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220127326A1 (en) | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof | |
| US8580922B2 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| ES3045508T3 (en) | Compositions and methods for internalizing enzymes | |
| US7981864B2 (en) | Methods and compositions for targeting proteins across the blood brain barrier | |
| EP3272773B1 (en) | Lyosomal targeting peptides and uses thereof | |
| AU2019202865B2 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| US11248029B2 (en) | ICAM-1 targeted fusion enzymes | |
| HK1232896B (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| HK1232896A1 (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| HK1193352A (en) | Peptide linkers for polypeptide compositions and methods for using same | |
| HK1193352B (en) | Peptide linkers for polypeptide compositions and methods for using same |